A- A A+

Schottland. National benchmarking report on implementation of the Medication Assisted Treatment (MAT) standards - 2021-22

An Experimental Statistics publication for Scotland. (Public Health Scotland, Schottland, 23-06-2022)

https://www.publichealthscotland.scot/publications/national-benchmarking-report-on-implementation-of-the-medication-assisted-treatment-mat-standards/national-benchmarking-report-on-implementation-of-the-medication-assisted-treatment-mat-standards/

Trends and Disparities in Access to Buprenorphine Treatment Following an Opioid-Related Emergency Department Visit Among an Insured Cohort, 2014-2020. 

Stevens MA, Tsai J, Savitz ST, Nath B, Melnick ER, D'Onofrio G, Jeffery MM. 

JAMA Netw Open. 2022 Jun 1;5(6):e2215287. doi: 10.1001/jamanetworkopen.2022.15287. PMID: 35657629.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792963

Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care. 

Taylor JL, Laks J, Christine PJ, Kehoe J, Evans J, Kim TW, Farrell NM, White CS, Weinstein ZM, Walley AY. 

Drug Alcohol Depend. 2022 May 14;236:109497. doi: 10.1016/j.drugalcdep.2022.109497. Epub ahead of print. PMID: 35607834.

https://www.sciencedirect.com/science/article/pii/S0376871622002344

Variations in national availability of waivered buprenorphine prescribers by racial and ethnic composition of zip codes. 

Hirchak KA, Amiri S, Kordas G, Oluwoye O, Lyons AJ, Bajet K, Hahn JA, McDonell MG, Campbell ANC, Venner K. 

Subst Abuse Treat Prev Policy. 2022 May 25;17(1):41. doi: 10.1186/s13011-022-00457-3. PMID: 35614487; PMCID: PMC9131568.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131568/

Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada. 

Sud A, McGee M, Mintzes B, Herder M. 

Int J Drug Policy. 2022 May 25;105:103749. doi: 10.1016/j.drugpo.2022.103749. Epub ahead of print. PMID: 35643048.

https://www.sciencedirect.com/science/article/pii/S0955395922001682

What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings. 

Hooker SA, Sherman MD, Lonergan-Cullum M, Nissly T, Levy R. 

J Subst Abuse Treat. 2022 May 20:108804. doi: 10.1016/j.jsat.2022.108804. Epub ahead of print. PMID: 35643586.

Abstract

https://pubmed.ncbi.nlm.nih.gov/35643586/

Integrating Routine Screening for Opioid Use Disorder into Primary Care Settings: Experiences from a National Cohort of Clinics. 

Austin EJ, Briggs ES, Ferro L, Barry P, Heald A, Curran GM, Saxon AJ, Fortney J, Ratzliff AD, Williams EC. 

J Gen Intern Med. 2022 May 25:1–9. doi: 10.1007/s11606-022-07675-2. Epub ahead of print. PMID: 35614169; PMCID: PMC9132563.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132563/

USA. The Methadone Clinic System Needs Abolition, Not a Tepid Reform Bill

Peter Vanderkloot’s groundbreaking article—Methadone: Medicine, Harm Reduction or Social Control—hit me hard. As a social worker, I helped people who used heroin get into methadone programs. His insightful analysis and refreshingly angry takedown of the United States methadone clinic system explained both negative interactions I’d had with clinic staff and traumatic incidents that clients shared with me. I go back and review the article often.

Vanderkloot describes in precise detail how clinic regulations disrupt and damage patients’ lives. He shows how a medication that embodies harm reduction is held hostage by a system of harm production. He knows what he’s talking about. For years, he’s stood in line waiting to be called to the plexiglass window by a nurse who pushes a plastic cup filled with red liquid through a chuckhole.

Then he drops this time bomb: “The methadone clinic system is a weapon of the drug warriors, and as long as it exists it will be used to control, degrade and injure.” Vanderkloot argues for the destruction of the clinic system and for methadone prescription parity. (Filter, USA, 23.05.2022)

https://filtermag.org/methadone-clinic-system-reform-bill/amp/

Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver. 

Lanham HJ, Papac J, Olmos DI, et al. 

JAMA Netw Open. 2022;5(5):e2212419. doi:10.1001/jamanetworkopen.2022.12419

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792215

"The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment. 

Suen LW, Castellanos S, Joshi N, Satterwhite S, Knight KR. 

Subst Abus. 2022;43(1):1143-1150. doi: 10.1080/08897077.2022.2060438. PMID: 35499469.

Abstract

https://www.tandfonline.com/doi/abs/10.1080/08897077.2022.2060438?journalCode=wsub20

Prehospital Buprenorphine Treatment for Opioid Use Disorder by Paramedics: First Year Results of the EMS Buprenorphine Use Pilot,

H. Gene Hern, Vanessa Lara, David Goldstein, M. Kalmin, S. Kidane, S. Shoptaw, Ori Tzvieli & Andrew A. Herring (2022)

Prehospital Emergency Care, DOI: 10.1080/10903127.2022.2061661

https://www.tandfonline.com/doi/full/10.1080/10903127.2022.2061661

Mobile Narcotic Treatment Programs: On the Road Again? 

Breve F, Batastini L, LeQuang JAK, Marchando G. 

Cureus. 2022 Mar 16;14(3):e23221. doi: 10.7759/cureus.23221. PMID: 35449647; PMCID: PMC9012571.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012571/

Structural violence and the need for compassionate use of methadone in Mexico. 

Romero-Mendoza M, Peláez-Ballestas I, Almanza-Avendaño AM, Figueroa E. 

BMC Public Health. 2022 Mar 29;22(1):606. doi: 10.1186/s12889-022-12955-x. PMID: 35351061; PMCID: PMC8962103.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962103/

Psychosocial functioning among current noninjecting opioid users: Is there any difference between methadone maintenance treatment and treatment as usual? 

Shukla R, Kar SK, Dalal PK, Arya A. 

Indian J Psychiatry. 2022 Jan-Feb;64(1):56-63. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_682_21. Epub 2022 Jan 21. PMID: 35400736; PMCID: PMC8992753.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992753/

Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder. 

Joudrey PJ, Kolak M, Lin Q, Paykin S, Anguiano V, Wang EA. 

JAMA Netw Open. 2022;5(4):e227028. doi:10.1001/jamanetworkopen.2022.7028

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2791296

USA. The Long Road to Methadone Access in Rural America

The U.S. has treatments to help people dealing with opioid addictions but throws up hurdles to access. (TNR, USA, 27.04.2022)

https://newrepublic.com/article/166210/methadone-access-rural-america-opioid-epidemic

USA. As a Methadone Patient, I Demand No Return to the Pre-COVID Status Quo

COVID-19 made us rethink how and why we were doing all kinds of things simply out of routine. Why do office workers have to commute to a desk to make a phone call? Why do folks need to go in person to therapy or to benefit appointments, if they can be done virtually? Why are methadone patients still largely attending clinics in person, up to six days a week, to receive their medication? (Filter, USA, 20.04.2022)

https://filtermag.org/methadone-patient-covid-rules

Australien. ‘Crisis looming’: GP calls for help as small band of doctors do heavy lifting on opioid treatment

A GP recognised for his work with people who abuse drugs is calling for more doctors to step up as demand for opioid treatment surges in the pandemic.

Dr Anthony Michaelson, who is being honoured with an Order of Australia for his service to the community for his pioneering drug abuse treatment programs, is one of a dwindling number of GPs who prescribes medication to treat opioid addiction in high numbers in Victoria. (The Age, Australien, 16.04.2022)

https://www.theage.com.au/national/victoria/crisis-looming-gp-calls-for-help-as-small-band-of-doctors-do-heavy-lifting-on-opioid-treatment-20220415-p5adr6.html

How do people who use drugs receiving Opioid Medication Therapy perceive their treatment? A multicentre study. 

Guillou Landreat M, Dany A, Challet Bouju G, Laforgue EJ, Cholet J, Leboucher J, Hardouin JB; OPAL Group, Victorri Vigneau C, Grall Bronnec M. 

Harm Reduct J. 2022 Mar 28;19(1):31. doi: 10.1186/s12954-022-00608-6. PMID: 35346219; PMCID: PMC8961988.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961988/

Treatment of Opioid Use Disorder in Canadian Psychosocial Addiction Programs: A National Survey of Policy, Attitudes, and Practice. 

Hodgins DC, Budd M, Czukar G, Dubreucq S, Jackson LA, Rush B, Quilty LC, Adams D, Cameron Wild T. 

Can J Psychiatry. 2022 Mar 8:7067437221082858. doi: 10.1177/07067437221082858. Epub ahead of print. PMID: 35257596.

https://journals.sagepub.com/doi/10.1177/07067437221082858

Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.

Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA. 

Addict Sci Clin Pract. 2022 Mar 7;17(1):15. doi: 10.1186/s13722-022-00299-1. PMID: 35255967; PMCID: PMC8899775.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899775/

Patient- and Provider-Reported Experiences of a Mobile Novel Digital Therapeutic in People With Opioid Use Disorder (reSET-O): Feasibility and Acceptability Study. 

Kawasaki S, Mills-Huffnagle S, Aydinoglo N, Maxin H, Nunes E. 

JMIR Form Res. 2022 Mar 25;6(3):e33073. doi: 10.2196/33073. PMID: 35333189.

https://formative.jmir.org/2022/3/e33073/

A Mixed-Methods Evaluation of the Feasibility of a Medical Management-Based Text Messaging Intervention Combined With Buprenorphine in Primary Care. 

Tofighi B, Durr M, Marini C, Lewis CF, Lee JD. 

Subst Abuse. 2022 Mar 26;16:11782218221078253. doi: 10.1177/11782218221078253. PMID: 35356483; PMCID: PMC8958716.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958716/

Structural violence and the need for compassionate use of methadone in Mexico. 

Romero-Mendoza M, Peláez-Ballestas I, Almanza-Avendaño AM, Figueroa E. 

BMC Public Health. 2022 Mar 29;22(1):606. doi: 10.1186/s12889-022-12955-x. PMID: 35351061; PMCID: PMC8962103.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962103/

Towards an Improved Substance Use Disorder Treatment Landscape in Rhode Island - Barriers, Current Progress, and Next Steps. 

Braun HM, Holtzman JA, Wunsch C, Clark SA. 

R I Med J (2013). 2022 Apr 1;105(3):24-27. PMID: 35349616.

http://rimed.org/rimedicaljournal/2022/04/2022-04-24-ethics-braun.pdf

The Methadone Manifesto: Treatment Experiences and Policy Recommendations From Methadone Patient Activists. 

Simon C, Vincent L, Coulter A, Salazar Z, Voyles N, Roberts L, Frank D, Brothers S. 

Am J Public Health. 2022 Apr;112(S2):S117-S122. doi: 10.2105/AJPH.2021.306665. PMID: 35349312; PMCID: PMC8965191.

https://ajph.aphapublications.org/doi/10.2105/AJPH.2021.306665

Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019. 

Mauro PM, Gutkind S, Annunziato EM, Samples H. 

JAMA Netw Open. 2022;5(3):e223821. doi:10.1001/jamanetworkopen.2022.3821

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790432

Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.

Gomes, T, McCormack, D, Bozinoff, N, Tadrous, M, Antoniou, T, Munro, C, et al.

Addiction. 2022; 1– 10. doi.org/10.1111/add.15862

https://onlinelibrary.wiley.com/doi/full/10.1111/add.15862

Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.

Gomes, T, McCormack, D, Bozinoff, N, Tadrous, M, Antoniou, T, Munro, C, et al. 

Addiction. 2022; 1– 10. doi.org/10.1111/add.15862

https://onlinelibrary.wiley.com/doi/full/10.1111/add.15862

USA. DEA’s Commitment to Expanding Access to Medication-Assisted Treatment

WASHINGTON – Today, Administrator Anne Milgram announced the Drug Enforcement Administration’s continued commitment to expanding access to medication-assisted treatment to help those suffering from substance use disorder.

“In this moment, when the United States is suffering tens of thousands of opioid-related overdose deaths every year, the DEA’s top priority is doing everything in our power to save lives,” said Administrator Milgram. “Medication-assisted treatment helps those who are fighting to overcome substance use disorder by sustaining recovery and preventing overdoses. At DEA, our goal is simple: we want medication-assisted treatment to be readily and safely available to anyone in the country who needs it.” (DEA – Drud Enforcement Administration, USA, 23.03.2022)

https://www.dea.gov/press-releases/2022/03/23/deas-commitment-expanding-access-medication-assisted-treatment